The global erythropoietin drug market is anticipated to grow at a considerable CAGR of around 5.6% during the forecast period. R&D departments of companies are working upon to develop biosimilar of erythropoietin drugs. They will prove a market driver in the forecast period as drugs by many pharmaceutical companies are costly. Treatment of chronic kidney disease, anemia caused by cancer needs erythropoietin drugs for increasing hemoglobin levels. Biosimilar will prove to be a low-cost alternative. They are easy to develop and require less time to gain approval as compared to biologics. Biologics are derived from living organisms such as humans, animals, microorganisms, or yeast. Characteristics, chemical identity, and bioactivity of biosimilars are compared with reference products by the state of the art technology.
Get Free Sample link @ https://www.omrglobal.com/request-sample/erythropoietin-drug-market
As per the Food and Drug Administration of the US, a reference product is a biological product that has been already approved. Comparison is made between reference products and biosimilar products. For instance, in Feb 2022, Biocon biologics, which is a subsidiary of Biocon, announced that it is going to acquire Viatris’ biosimilar business for $3.3 billion. Studies are conducted by medical research agencies and institutions which are showing positive results are also paving the way to an increase in biosimilar in coming times. For instance, in Feb 2022, a comparative study and analysis were made in between Pan Gen Biotech’s epoetin alfa biosimilar which was PDA10. The reference product was Epogen. Both the products saw equal efficacy and safety.
Full report of Erythropoietin Drug Market available @ https://www.omrglobal.com/industry-reports/erythropoietin-drug-market
Market Coverage
- Segment Covered-
o By Product type
o By Application
- Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape- Amgen Inc., Johnson & Johnson, Hospira Inc., F.Hoffman-La Roche AG, LG Chem, and others
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How COVID-19 impact the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Erythropoietin Drug Market Report by Segment
By Product type
- Epoetin alfa
- Epoetin beta
- Darbepoetin-alfa
By Application
- Hematology
- Kidney Disorders
- Cancer
Reasons to Buying From us –
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/erythropoietin-drug-market
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.